Tags

Type your tag names separated by a space and hit enter

Finasteride in the treatment of hirsutism: new therapeutic perspectives.
Fertil Steril. 1996 Jul; 66(1):61-5.FS

Abstract

OBJECTIVE

To determine of the clinical and hormonal effects of finasteride (Proscar; Merck, Sharp, and Dohme, Rahway, NJ) in the treatment of idiopathic hirsutism and hirsutism in patients with polycystic ovary syndrome (PCOS).

DESIGN

Controlled clinical study.

SETTING

Istitute of Obstetrics and Gynecology, University of Naples "Federico II."

PATIENTS

Ten women affected by idiopathic hirsutism and 15 women with PCOS.

INTERVENTIONS

Finasteride was administered orally at a daily dose of 5 mg for a period of 6 months.

MAIN OUTCOME MEASURES

Rating of hirsutism with the Ferriman-Gallwey method; serum androgen assays.

RESULTS

Finasteride produced a reduction in the average hirsutism scores (> 50% in all patients), whereas no change was observed in serum T, androstenedione, and DHEAS levels. A significant reduction was measured in serum dihydrotestosterone and 3 alpha, 17 beta-androstenediol glucuronide levels.

CONCLUSIONS

This study demonstrates that symptomatic hirsutism has to be considered as a skin disease associated with the increased activity of the 5 alpha-reductase. It also indicates that the selective 5 alpha-reductase inhibitor, finasteride, is very effective and well tolerated in the treatment of both idiopathic hirsutism and of hirsutism in patients with PCOS.

Links

Publisher Full Text

Authors+Show Affiliations

Tolino A
Department of Obstetrics and Gynecology, University of Naples Federico II, Italy.
Petrone A
No affiliation info available
Sarnacchiaro F
No affiliation info available
Cirillo D
No affiliation info available
Ronsini S
No affiliation info available
Lombardi G
No affiliation info available
Nappi C
No affiliation info available

MeSH

AdultAndrogensEnzyme InhibitorsFemaleFinasterideHirsutismHumansPolycystic Ovary SyndromeTreatment Outcome

Pub Type(s)

Clinical Trial
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

8752612

Citation

Tolino, A, et al. "Finasteride in the Treatment of Hirsutism: New Therapeutic Perspectives." Fertility and Sterility, vol. 66, no. 1, 1996, pp. 61-5.
Tolino A, Petrone A, Sarnacchiaro F, et al. Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril. 1996;66(1):61-5.
Tolino, A., Petrone, A., Sarnacchiaro, F., Cirillo, D., Ronsini, S., Lombardi, G., & Nappi, C. (1996). Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertility and Sterility, 66(1), 61-5.
Tolino A, et al. Finasteride in the Treatment of Hirsutism: New Therapeutic Perspectives. Fertil Steril. 1996;66(1):61-5. PubMed PMID: 8752612.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Finasteride in the treatment of hirsutism: new therapeutic perspectives. AU - Tolino,A, AU - Petrone,A, AU - Sarnacchiaro,F, AU - Cirillo,D, AU - Ronsini,S, AU - Lombardi,G, AU - Nappi,C, PY - 1996/7/1/pubmed PY - 1996/7/1/medline PY - 1996/7/1/entrez SP - 61 EP - 5 JF - Fertility and sterility JO - Fertil Steril VL - 66 IS - 1 N2 - OBJECTIVE: To determine of the clinical and hormonal effects of finasteride (Proscar; Merck, Sharp, and Dohme, Rahway, NJ) in the treatment of idiopathic hirsutism and hirsutism in patients with polycystic ovary syndrome (PCOS). DESIGN: Controlled clinical study. SETTING: Istitute of Obstetrics and Gynecology, University of Naples "Federico II." PATIENTS: Ten women affected by idiopathic hirsutism and 15 women with PCOS. INTERVENTIONS: Finasteride was administered orally at a daily dose of 5 mg for a period of 6 months. MAIN OUTCOME MEASURES: Rating of hirsutism with the Ferriman-Gallwey method; serum androgen assays. RESULTS: Finasteride produced a reduction in the average hirsutism scores (> 50% in all patients), whereas no change was observed in serum T, androstenedione, and DHEAS levels. A significant reduction was measured in serum dihydrotestosterone and 3 alpha, 17 beta-androstenediol glucuronide levels. CONCLUSIONS: This study demonstrates that symptomatic hirsutism has to be considered as a skin disease associated with the increased activity of the 5 alpha-reductase. It also indicates that the selective 5 alpha-reductase inhibitor, finasteride, is very effective and well tolerated in the treatment of both idiopathic hirsutism and of hirsutism in patients with PCOS. SN - 0015-0282 UR - https://www.unboundmedicine.com/medline/citation/8752612/Finasteride_in_the_treatment_of_hirsutism:_new_therapeutic_perspectives_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(16)58388-5 DB - PRIME DP - Unbound Medicine ER -